


Supernus Pharmaceuticals



Overview Presentation

May 2020

Safe Harbor Statement

This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus' business strategy, goals and expectations concerning its product candidates, ability to integrate the acquired portfolio into its infrastructure, future operations, prospects, plans and objectives of management. The words "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "will", and similar terms and phrases are used to identify forward-looking statements in this presentation. Supernus' operations involve risks and uncertainties, many of which are outside its control, including the potential impact of COVID-19, and any one of which, or a combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Supernus assumes no obligation to update any forward-looking statements except as required by applicable law.

Supernus has filed with the U.S. Securities and Exchange Commission (SEC) reports and other documents required by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. Before you purchase any Supernus securities, you should read such reports and other documents to obtain more complete information about the company's operations and business and the risks and uncertainties that it faces in implementing its business plan. You may get these documents for free by visiting EDGAR on the SEC website at <http://www.sec.gov>.



Proven Execution in CNS & ADHD

20+ Years of CNS experience including Four Programs in ADHD

<p>2005 to Present</p>		 	<p>SPN-812</p> <p>SPN-820</p> <p>SPN-817</p>
<p>1997 to 2005</p>		 	 


For several years, and prior to becoming independent in 2005, Supernus operated as Shire Laboratories, Inc., a division of Shire. SPN-812, SPN-820, and SPN-817 are product candidates in various stages of development. All trademarks are the property of their respective owners




Profitable CNS Company

Sales and Operating Earnings Performance

Total Net Product Sales (\$ Millions)



Total Operating Earnings (\$ Millions)




*Year-end 2018 inventory build by distribution channel increased 2018 net sales by approximately \$10 million and negatively impacted 2019 net sales.

© 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved.



Trokendi XR and Oxtellar XR Prescription Growth



Source: IQVIA Monthly Prescriptions - Include restatement for 2017 and 2018 by IQVIA



© 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved.



Trokendi XR

More Favorable Clinical Outcomes Compared to TPM-IR¹

Side Effects with Trokendi XR vs. TPM-IR in Migraine Cohort (n=124)



Median Monthly Migraine Frequency
 Pre- vs. Post-Initiation of Trokendi XR

¹ O'Neal W et al. Cognitive tolerability and health outcomes with Trokendi XR (extended-release topiramate) in migraineurs. J Pain 2017; 18(4): S67. Retrospective Medical Chart Review

TPM-IR = Topiramate immediate release



Trokendi XR

Use in Clinical Practice – A Pragmatic Assessment¹


Responder Rate	% of Patients
≥ 50% Reduction	55
≥ 75% Reduction	41
100% Reduction	24

* Responder Rate: percent change from pre-index migraine frequency associated with Trokendi XR treatment (n=159)

¹ O'Neal W et al. Pragmatic assessment of Trokendi XR (extended-release topiramate) in migraine prevention. Poster presented at 59th Annual Scientific Meeting of the American Headache Society, June 2017

Oxtellar XR

Improved Adverse Event Profile at Double the Dose of Trileptal[®]



Based on comparison of Oxtellar XR (SPN-804O) Phase III vs. Trileptal PI (adjunctive therapy study in adults); differences in trial design exist between the two studies. Dizziness includes vertigo in Trileptal group because of change in the MedDRA system



© 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved.



Monotherapy Epilepsy Market Opportunity

69% of Partial Seizure Prescriptions Are For Monotherapy

Partial Seizure Prescriptions 22M Annually



Oxcarbazepine – Studied in Monotherapy with 8 Positive Clinical Trials²

IMS NDTI MAT12 months

¹ Using a branded TRx at \$450 Net

² Glauser TA. *Pharmacother.* 2001;21:904-919

Acquisition U.S. CNS Portfolio of US WorldMeds¹

- **Creates leading CNS portfolio**
 - 5 marketed products / Strong strategic fit / Late-stage pipeline
- **Adds new growth catalysts**
 - Apomorphine infusion pump H2 2021
 - MYOBLOC® in additional neurological disorders
- **Diversifies and increases revenue base**
 - 39% increase in revenue base²
- **Diversifies and increases free cash flow**
- **Deal structure aligns milestones with future upside**
 - Upfront payment \$300M
 - Regulatory & commercial milestone payments up to \$230M

1. Transaction expected to close Q2 2020

2. 2019 annual proforma basis

A Comprehensive Commercial Platform in CNS



Acquired Portfolio

Sales Force

- Sales force over 200 representatives
- Targeting primarily neurologists, to support epilepsy and migraine franchise

- Sales force of ~46 representatives
- Targeting movement disorder specialists with selective coverage of neurologists

Marketed Products



- Retail distribution
- HCP & consumer media



- Orphan drug
- Specialty pharmacy
- "Buy & Bill"
- Nurse network
- Fulfillment hub

Full Patient Support Capabilities



A Robust R&D Pipeline & Platform in CNS



Pipeline & R&D Platform

- **SPN-812**
 - PDUFA Nov. 8, 2020, ADHD
- **SPN-820**
 - NV-5138 Phase I, Treatment-Resistant Depression
- **SPN-817**
 - Phase I, Epilepsy
- **Apomorphine Infusion Pump**
 - Parkinson's disease
 - Launch expected in H2 2021



Small Molecule, Biologics, Device, Drug Delivery Capabilities



CNS Portfolio of US WorldMeds Adds Robust Neurology Portfolio with Near Term New Product Launches

2019 Net Sales: ~\$150 million Operating Earnings: ~\$45 million



- Apomorphine hydrochloride subcutaneous injection for acute intermittent treatment of symptoms of “off” episodes with advanced Parkinson’s disease (PD)



- Injectable neurotoxin type B indicated for the treatment of adults with cervical dystonia and recently approved for chronic sialorrhea in adults

Apomorphine Subcutaneous Infusion Pump

- Apomorphine hydrochloride continuous subcutaneous infusion
 - Expected NDA filing in H2 2020
 - Expected launch in H2 2021



- Monoamine oxidase type B inhibitor indicated for adjunctive treatment of adults with PD to limit “off” episodes

APOKYN Pen and apomorphine product candidate are under a license from Britannia Pharmaceuticals Ltd.


Xadago under a license from Zambon S.p.A

All trademarks are the property of their respective owners

© 2020 Supernus Pharmaceuticals, Inc. All Rights Reserved.



Addressing Patient Needs at Different Stages of Parkinson's Disease



Parkinson's Disease (PD) Market

- U.S. PD Market is anticipated to grow from \$1.5B to \$6.2B by 2026¹
- Second most common chronic progressive neurodegenerative disorder, affecting 1-2% of individuals 65 years and older²
- ~1M U.S. PD patients (2020), ~2.5%¹ annual growth rate
- PD occurs when cells in the brain, which produce dopamine, become impaired or die
- The mainstay for therapy is levodopa with effectiveness wearing off resulting in “OFF” periods
- As PD advances, patients experience more “OFF” periods

1. Global Data Parkinson's Disease Global Drug Forecast and Market Analysis 2026

2. Saxton JM. Exercise and Chronic Disease: an Evidence-Based Approach. London, Routledge, 2011

SPN-812

Novel Non-Stimulant ADHD Product Candidate

- Viloxazine hydrochloride
 - Serotonin norepinephrine modulating agent (SNMA)
 - New Chemical Entity (NCE)
 - Previously marketed outside the US as an antidepressant
- Building strong IP with expirations from 2029-2033
- NDA under review by FDA with a PDUFA of November 8, 2020
- Phase III clinical data point to a well-differentiated ADHD product
 - 100mg, 200mg and 400mg in pediatric patients
 - Unique mechanism of action
 - Consistent & reliable efficacy with robust statistical significance
 - Efficacy on both Hyperactivity/Impulsivity and Inattention
 - Fast onset of action
 - Well tolerated

SPN-812

Significant Market Opportunity

	Percent	Estimated Prescriptions in Peak Year
ADHD Market Prescriptions		89 - 100 Million
	Peak Market Share	SPN-812 Potential Prescriptions
SPN-812 Peak Demand	5 - 10%	4.5 - 10.0 Million

Source: IMS NPA, Company Research and Estimates – Assumes peak at 3-7 years post launch
Figures in the table above represent management's estimates that are subject to several factors that are beyond our control and actual results may be significantly different from our estimates

SPN-820


Novel MOA for Treatment-Resistant Depression (TRD)

- Joint development and option agreement with Navitor Pharmaceuticals
- First-in-class selective brain mTORC1 activator
 - Binds to and modulates sestrin, a leucine amino acid sensor
- New chemical entity, long IP runway
- Early efficacy signal on HAM-D-6 scale in TRD patients
 - Rapid onset of action (signal at 2 hours)
 - Meaningful effect sizes (>0.4 through 3 days on 1 dose)
- Significant market need & revenue potential
 - ~30% of MDD patients are treatment resistant

Depression

- Chronic debilitating illness and a leading cause of disability
 - Low mood, feelings of guilt and worthlessness, low energy, problems with sleep, and other emotional and physical symptoms
- In severe cases, the disease can lead to suicide
- The prevalence of major depression is ~15 million in the U.S., approximately 5% to 8% of the adult population
- The treatment-resistant market is estimated at 5 million+ TRx
- Contributes significant costs, morbidity, and mortality

Positioned For Long-Term Growth



Diversified Neurology Portfolio

Oxtellar XR[®], Trokendi XR[®], APOKYN[®], MYOBLOC[®], XADAGO[®]

Innovative Pipeline in CNS

SPN-812

Apomorphine Infusion Pump

MYOBLOC

SPN-817

SPN-820 (NV-5138)

Potential Launch in 2020

Potential Launch in 2021

Neurological Disorders

Appendix

SPN-812

Phase III Studies

	P301 N = 477	P303 N = 313	P302 N = 310	P304 N = 297
ADHD Patients	6-11 years	6-11 years	12-17 years	12-17 years
Daily Doses	100mg 200mg	200mg 400mg	200mg 400mg	400mg 600mg
Status	Completed	Completed	Completed	Completed

Randomized, double-blind, placebo-controlled, multicenter, parallel group, monotherapy for ADHD
 Primary Endpoint - Change from baseline on ADHD-RS-5 scale compared to placebo



SPN-812 Phase III Data: Primary Endpoint

P301 (Children)	Statistics	Placebo (N=155)	100 mg (N=147)	200 mg (N=158)
Week 6 (EOS)	LS Mean	-10.9	-16.6	-17.7
	p-value		0.0004	<.0001
P302 (Adolescent)	Statistics	Placebo (N=104)	200 mg (N=94)	400 mg (N=103)
Week 6 (EOS)	LS Mean	-11.4	-16.0	-16.5
	p-value		0.0232	0.0091
P303 (Children)	Statistics	Placebo (N=97)	200 mg (N=107)	400 mg (N=97)
Week 8 (EOS)	LS Mean	-11.7	-17.6	-17.5
	p-value		0.0038	0.0063
P304 (Adolescent)	Statistics	Placebo (N=97)	400 mg (N=99)	600 mg (N=97)
Week 7 (EOS)	LS Mean	-13.2	-18.3	-16.7
	p-value		0.0082	0.0712

Primary Analysis of ADHD-RS-5 based on Mixed Model for Repeated Measure (MMRM) Intent to Treat (ITT Population)
EOS = End of Study



SPN-812 Phase III Data

Significant Reduction in Hyperactivity and Inattention

Analysis in ADHD-RS-5 Inattention and Hyperactivity/Impulsivity Subscales

P301 Week 6 (EOS)	Statistics	100 mg (N=147)	200 mg (N=158)
Hyperactivity/Impulsivity	p-value	0.0026	<.0001
Inattention	p-value	0.0006	<.0001

P302 Week 6 (EOS)	Statistics	200 mg (N=94)	400 mg (N=103)
Hyperactivity/Impulsivity	p-value	0.0069	0.0005
Inattention	p-value	0.0424	0.0390

P303 Week 8 (EOS)	Statistics	200 mg (N=107)	400 mg (N=97)
Hyperactivity/Impulsivity	p-value	0.0020	0.0039
Inattention	p-value	0.0087	0.0248

P304 Week 7 (EOS)	Statistics	400 mg (N=99)	600 mg (N=97)
Hyperactivity/Impulsivity	p-value	0.0484	0.2084
Inattention	p-value	0.0042	0.1392

EOS = End of Study



SPN-812 Phase III Data: Fast Onset of Action

Efficacy Starting in Week 1 - ADHD-RS-5 Total Score

Pooled Data – P301, P302, P303, P304				
Visit	Statistics	Placebo (N=452)	200 mg (N=359)	400 mg (N=299)
Baseline	Mean	41.8	42.9	41.8
Week 1	p-value		0.0003	0.0016
Week 2	p-value		<.0001	<.0001
Week 3	p-value		<.0001	<.0001
Week 4	p-value		<.0001	<.0001
Week 5	p-value		<.0001	<.0001
Week 6	LS Mean	-11.7	-17.1	-17.7
	p-value		<.0001	<.0001

P301	
Placebo (N=155)	100 mg (N=147)
43.6	45.0
	0.0004
	<.0001
	<.0001
	<.0001
	0.0006
-10.9	-16.6
	0.0004

- Common endpoint visit for all four studies is Week 6
- Pooled Data exclude 100 mg and 600 mg that were tested in one study only
- Primary Analysis of ADHD-RS-5 in Intent to Treat Population



SPN-812 Phase III Data: Fast Onset of Action

Efficacy Starting in Week 1 - Inattention Subscale

Pooled Data – P301, P302, P303, P304				
Visit	Statistics	Placebo (N=452)	200 mg (N=359)	400 mg (N=299)
Baseline	Mean	22.4	22.6	22.3
Week 1	p-value		0.0086	0.0162
Week 2	p-value		0.0001	<.0001
Week 3	p-value		<.0001	<.0001
Week 4	p-value		<.0001	<.0001
Week 5	p-value		<.0001	<.0001
Week 6	LS Mean	-6.4	-8.9	-9.2
	p-value		<.0001	<.0001

P301	
Placebo (N=155)	100 mg (N=147)
22.5	22.8
	0.0016
	0.0016
	0.0002
	<0.0001
	0.0018
-5.6	-8.6
	0.0006

- Common endpoint visit for all four studies is Week 6
- Pooled Data exclude 100 mg and 600 mg that were tested in one study only
- Primary Analysis of ADHD-RS-5 in Intent to Treat Population



SPN-812 Phase III Data: Fast Onset of Action

Efficacy Starting in Week 1 - Hyperactivity/Impulsivity Subscale

Pooled Data – P301, P302, P303, P304				
Visit	Statistics	Placebo (N=452)	200 mg (N=359)	400 mg (N=299)
Baseline	Mean	19.4	20.3	19.5
Week 1	p-value		<.0001	0.0010
Week 2	p-value		<.0001	<.0001
Week 3	p-value		<.0001	<.0001
Week 4	p-value		<.0001	<.0001
Week 5	p-value		<.0001	<.0001
Week 6	LS Mean	-5.4	-8.2	-8.5
	p-value		<.0001	<.0001

P301	
Placebo (N=155)	100 mg (N=147)
21.1	22.2
	0.0023
	<0.0001
	<0.0001
	0.0004
	0.0010
-5.3	-8.0
	0.0014

- Common endpoint visit for all four studies is Week 6
- Pooled Data exclude 100 mg and 600 mg that were tested in one study only
- Primary Analysis of ADHD-RS-5 in Intent to Treat Population

SPN-812 Phase III Data: Secondary Endpoint

Analysis of Observed Global Improvement Score (CGI-I) at EOS

P301	Statistics	Placebo (N=155)	100 mg (N=147)	200 mg (N=158)
Week 6 (EOS)	LS Mean	3.1	2.7	2.6
	p-value		0.0020	<.0001
P302	Statistics	Placebo (N=104)	200 mg (N=94)	400 mg (N=103)
Week 6 (EOS)	LS Mean	3.0	2.5	2.4
	p-value		0.0042	0.0003
P303	Statistics	Placebo (N=97)	200 mg (N=107)	400 mg (N=97)
Week 8 (EOS)	LS Mean	3.1	2.6	2.6
	p-value		0.0028	0.0099
P304	Statistics	Placebo (N=96)	400 mg (N=99)	600 mg (N=97)
Week 7 (EOS)	LS Mean	2.9	2.4	2.6
	p-value		0.0051	0.0995

EOS = End of Study



SPN-812

Summary of Treatment Related Adverse Events

Number (%) of Patients - Treatment Related AEs with $\geq 5\%$ Incidence *All Four Phase III Trials*

	Placebo (N=463)	SPN-812 (N=925)
Somnolence	14 (3.0)	115 (12.4)
Decreased appetite	2 (0.4)	61 (6.6)
Headache	14 (3.0)	57 (6.2)
Fatigue	10 (2.2)	56 (6.1)
Discontinuation due to AEs	6 (1.3)	32 (3.5)

AEs = Adverse Events